Denmark· DK-28101540293

Adenocor

A adenosine product containing adenosin, registered in Denmark by Sanofi A/S. The same ATC class is registered in 16 of our 19 countries.

ATC C01EB10

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedAdenocorATCC01EB10REGISTER NO.DK-28101540293PACKS LISTED1CHECKEDSeptember 30, 2026

Where it is registered

Adenosine is registered in 16 of 19 countries.

Countries holding a registration under ATC C01EB10 (adenosine), each read from that country’s own register.

  • This record: Denmark, from Danish Medicines Agency (Denmark)
  • 8 of them publish a price we can compare per daily dose

Adenosine · ATC C01EB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
ADENOSIN
Manufacturer
Sanofi A/S
Country
Denmark (DK)
ATC code
C01EB10
ATC class
Adenosine
Defined daily dose
15 mg, P
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28101540293

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

181 interactions on record for adenosine.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Adenosine · interactions on record

181 records

  • 38 severe
  • 90 moderate
  • 1 minor
  • 52 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/25ebd7c3-d730-4ab5-99f2-7fcc31202028
GET /v1/drugs/25ebd7c3-d730-4ab5-99f2-7fcc31202028?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "injektionsvæske, opløsning",
  "source": "dkma",
  "strength": "3 mg/ml",
  "auth_role": "DKMA",
  "dk_drugid": "28101540293",
  "substance": "ADENOSIN",
  "auth_procedure": "National",
  "in_medicinpriser": true,
  "registration_date_serial": "34536"
}

See everything about adenosine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.